Tislelizumab Combined With Chemotherapy for Resectable Esophageal Squamous Cell Carcinoma Followed by CRT or Surgery

Authors
Category Primary study
Registry of TrialsClinicalTrials.gov
Year 2025
To explore the non-inferiority of the 2y-OS rate of tislelizumab combined with chemotherapy after sequential CRT in the treatment of resectable esophageal squamous cell carcinoma compared with the surgical group
Epistemonikos ID: 46bef09871422364526e27d06cb6fc58b795b95c
First added on: Jul 02, 2025